Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing observational study of RECARBRIO in Chinese adults with limited-treatment-option susceptible Gram-negative bacterial infections
ChiCTR2600135084Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of imipenem in hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), Intra-abdominal infection (IAI) and 3 more, sponsored by Huashan Hospital. Primary endpoints: Clinical response at end of treatment and Clinical response at test of cure. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
imipenem
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)Intra-abdominal infection (IAI)complicated urinary tract infection (cUTI)pyelonephritis
Beyond the preview
Go deeper on ChiCTR2600135084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135084.